GlassScriptPhysician profile
Priya Tarun Mehta
NPI 1851741532
$17,816.73
in general payments reported to CMS, 2019-2025
14 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.73 · 2020: $96.67 · 2021: $11.23 · 2022: $500 · 2023: $274 · 2024: $5,482 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,890 · Food and Beverage: $3,597 · Consulting Fee: $3,440 · Travel and Lodging: $1,087 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,890.00 |
| Food and Beverage | $3,596.74 |
| Consulting Fee | $3,440.00 |
| Travel and Lodging | $1,087.11 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,861.40 | 2022-2025 | Xolair |
| Genzyme Corporation | $955.96 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $793.24 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $587.55 | 2019-2025 | Dupixent |
| Amgen INC. | $132.98 | 2022-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $120.59 | 2020-2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $88.88 | 2022-2025 | |
| Organon LLC | $69.73 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $63.66 | 2019-2024 | Nucala |
| Kaleo, INC. | $46.25 | 2024 | Auvi-Q |
| Horizon Therapeutics Plc | $45.71 | 2019 | |
| Pfizer INC. | $22.63 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.92 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.